INTRODUCTION: For anticancer drug development, it is crucial that patients participate in early-phase clinical trials. The main aim of this study was to gain insight into the motivations and other variables influencing patients in their decision to participate in phase I oncology trials. MATERIALS AND METHODS: Over a period of 25 months, all patients who were informed about (specific) phase I trials in our cancer center were retrospectively included in this study. Data on providing informed consent and final phase I enrollment were collected. RESULTS: In total, 365 patients, with a median age of 59 years and a median World Health Organization performance status score of 1, were evaluated. The majority of patients (71%) were pretreated with systemic therapy, with a median of two lines. After specific study information had been given, 145 patients (40%) declined informed consent, 54% of them mainly because of low expectations regarding treatment benefits and concerns about potential side effects. Patients who had received previous systemic therapy consented more frequently than others. After initial consent, 61 patients (17%) still did not receive study treatment, mostly because of secondary withdrawal of consent or rapid clinical deterioration prior to first dosing. DISCUSSION: After specific referral to our hospital for participation in early clinical trials, only 44% of all patients who were informed about a specific phase I trial eventually participated. Reasons for both participation and nonparticipation were diverse. Patient participation rates could be improved by forming an experienced and dedicated study team.
INTRODUCTION: For anticancer drug development, it is crucial that patients participate in early-phase clinical trials. The main aim of this study was to gain insight into the motivations and other variables influencing patients in their decision to participate in phase I oncology trials. MATERIALS AND METHODS: Over a period of 25 months, all patients who were informed about (specific) phase I trials in our cancer center were retrospectively included in this study. Data on providing informed consent and final phase I enrollment were collected. RESULTS: In total, 365 patients, with a median age of 59 years and a median World Health Organization performance status score of 1, were evaluated. The majority of patients (71%) were pretreated with systemic therapy, with a median of two lines. After specific study information had been given, 145 patients (40%) declined informed consent, 54% of them mainly because of low expectations regarding treatment benefits and concerns about potential side effects. Patients who had received previous systemic therapy consented more frequently than others. After initial consent, 61 patients (17%) still did not receive study treatment, mostly because of secondary withdrawal of consent or rapid clinical deterioration prior to first dosing. DISCUSSION: After specific referral to our hospital for participation in early clinical trials, only 44% of all patients who were informed about a specific phase I trial eventually participated. Reasons for both participation and nonparticipation were diverse. Patient participation rates could be improved by forming an experienced and dedicated study team.
Authors: Daniel P Sulmasy; Alan B Astrow; M Kai He; Damon M Seils; Neal J Meropol; Ellyn Micco; Kevin P Weinfurt Journal: Cancer Date: 2010-08-01 Impact factor: 6.860
Authors: Bassel F El-Rayes; Pallavi Jasti; Richard K Severson; Khaldoun Almhanna; Philip A Philip; Anthony Shields; Mark Zalupski; Lance K Heilbrun Journal: Pancreas Date: 2010-10 Impact factor: 3.327
Authors: Thomas G Roberts; Bernardo H Goulart; Lee Squitieri; Sarah C Stallings; Elkan F Halpern; Bruce A Chabner; G Scott Gazelle; Stan N Finkelstein; Jeffrey W Clark Journal: JAMA Date: 2004-11-03 Impact factor: 56.272
Authors: Addie C Wootten; Jo M Abbott; Heather M Siddons; Mark A Rosenthal; Anthony J Costello Journal: Support Care Cancer Date: 2009-12-04 Impact factor: 3.603
Authors: Vasilios Karavasilis; Laurence Digue; Tobias Arkenau; David Eaton; Sarah Stapleton; Johann de Bono; Ian Judson; Stan Kaye Journal: Eur J Cancer Date: 2008-03-24 Impact factor: 9.162
Authors: Jeremy Ho; Gregory R Pond; Colin Newman; Martha Maclean; Eric X Chen; Amit M Oza; Lillian L Siu Journal: BMC Cancer Date: 2006-11-08 Impact factor: 4.430
Authors: A Schwandt; P J Harris; S Hunsberger; A Deleporte; G L Smith; D Vulih; B D Anderson; S P Ivy Journal: Clin Cancer Res Date: 2014-07-15 Impact factor: 12.531
Authors: Sarah B Garrett; Thea M Matthews; Corey M Abramson; Christopher J Koenig; Fay J Hlubocky; Christopher K Daugherty; Pamela N Munster; Daniel Dohan Journal: JCO Oncol Pract Date: 2019-10-11
Authors: Siqing Fu; Lacey McQuinn; Aung Naing; Jennifer J Wheler; Filip Janku; Gerald S Falchook; Sarina A Piha-Paul; Dennis Tu; Adrienne Howard; Apostolia Tsimberidou; Ralph Zinner; David S Hong; Razelle Kurzrock Journal: Oncologist Date: 2013-10-23
Authors: Lynn A Jansen; Daruka Mahadevan; Paul S Appelbaum; William M P Klein; Neil D Weinstein; Motomi Mori; Catherine Degnin; Daniel P Sulmasy Journal: J Empir Res Hum Res Ethics Date: 2017-07-21 Impact factor: 1.742
Authors: Cora Braat; Gerda M Verduijn; Heleen A van der Stege; Marinella P J Offerman; Mariëlle A C Peeters; AnneLoes van Staa; Wendy H Oldenmenger Journal: Cancer Nurs Date: 2022 Mar-Apr 01 Impact factor: 2.760
Authors: Gisell Castillo; Manoj M Lalu; Sarah Asad; Madison Foster; Natasha Kekre; Dean A Fergusson; Terry Hawrysh; Harold Atkins; Kednapa Thavorn; Joshua Montroy; Stuart Schwartz; Robert A Holt; Raewyn Broady; Justin Presseau Journal: BMJ Open Date: 2021-03-19 Impact factor: 2.692